NCT01496053已完成2 期
Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study
Oslo University Hospital2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2011年12月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Reduction in biochemical blood parameters (pro-inflammatory cytokines)
研究概览
简要总结
Examine whether daily oral ingestion of a immunomodulatory mushroom extract (AndoSanTM) in patients with ulcerative colitis (UC) and Crohn's disease (CD), experience clinical, biochemical and genetical improvement in their disease.
A prospective randomised study comparing the mushroom extract with placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •moderate disease
排除标准
- •serious disease,
- •biological treatment,
- •pregnancy.
结局指标
主要结局
Reduction in biochemical blood parameters (pro-inflammatory cytokines)
时间窗: 21 days
次要结局
- Reduction of calprotectin in feces.(21 days)
- Clinical symptom score.(21 days)
研究者
Egil Johnson
MD, Phd
Oslo University Hospital
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Andosan in Allergic and Asthma PatientsImmune ToleranceAllergic RhinoconjunctivitisAllergic AsthmaNCT05192720University Hospital, Akershus34
已完成
不适用
Effect of Andosan in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT01815411Egil Johnson10
已完成
2 期
Agaricus Blazei Murill (ABM) in Patients With Inflammatory Bowel Disease (IBD)Inflammatory Bowel DiseaseNCT01106742Ullevaal University Hospital20
已完成
不适用
Immune Benefits From Mushroom ConsumptionHealthy HumansNCT01398176University of Florida52
已完成
2 期
Agaricus Blazei Murill in Patients With Multiple MyelomaMultiple MyelomaNCT00970021Ullevaal University Hospital39